FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - Foley Hoag
FDA proposes to eliminate the 'adequate provision' requirement for broadcast prescription drug advertising, which currently allows drug makers to include a brief summary or provide information via toll-free number or website. This change would require all broadcast ads to include major statements about side effects and contraindications, potentially increasing ad costs and complexity.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 25, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that engage in direct-to-consumer broadcast advertising should confirm how it applies to their specific situation before acting. There is a time constraint attached: Proposal is open for comment; final rule expected within 12-18 months. Monitor Federal Register for comment period end date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA proposes to remove the 'adequate provision' option, requiring broadcast ads to include all major risk information directly in the ad, rather than providing a brief summary or alternative access.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) that engage in direct-to-consumer broadcast advertising
What you must do
Review current broadcast advertising strategies and prepare for potential new requirements. Begin assessing ad formats and budgets to accommodate longer risk disclosures.
Deadline
Proposal is open for comment; final rule expected within 12-18 months. Monitor Federal Register for comment period end date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS S5004: Cancer Drug Parity Act of 2026
- US-CONGRESS BILLS-119hr8205eh: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- US-CONGRESS S5043: Secure Drug Supply Chain Act of 2026
- FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs - JD Supra
- Order: Francis Esteban Matos: Final Debarment